Results 161 to 170 of about 451,760 (295)

FoxP3+ Regulatory T-Cells in Canine Cutaneous Lymphoma and Their Role in Immune Modulation. [PDF]

In Vivo
Semolin LMS, Anai LA, Jark PC, Munhoz TD, Cruvinel GG, Bitencourt RC, DA Rosa Sobreira MF, Camplesi AC, Leitão JR, Santana AE, Alves CEF.   +10 more
europepmc   +1 more source

Management of Non‐Plaque‐Induced Gingival Conditions: A Systematic Review—Part 2: Inflammatory and Immune Conditions; Neoplasms; and Gingival Pigmentation

Journal of Clinical Periodontology, EarlyView.
ABSTRACT Aims This systematic review assesses current evidence on the management of non‐plaque (dental biofilm)‐induced gingival diseases and conditions (NPIGDs), including (i) inflammatory and immune conditions, (ii) neoplasms and (iii) gingival pigmentations.
Maria Clotilde Carra, Cecile Wasielewski, Bruno Špiljak, Maja Sabalić‐Schoener, Sebastien Jungo, Ivan Alajbeg   +5 more
wiley   +1 more source

European S2k guidelines for hidradenitis suppurativa/acne inversa Part 1. Epidemiology, diagnosis and clinical assessment

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Updated S2k hidradenitis suppurativa (HS) guidelines provide expert consensus on diagnosis, assessment and comorbidities. Expanded substantially since the 2015 version, they reflect rapid growth in HS literature and aim to improve generalist‐level patient care through evidence‐informed, consensus‐based guidance.
G. B. E. Jemec, B. Villumsen, K. R. van Straalen, H. H. van der Zee, S. Valiukevičienė, T. Tzellos, J. C. Szepietowski, A. Szegedi, D. M. L. Saunte, M. Romanelli, H. Raynal, F. Prignano, E. P. Prens, M. Podda, A. Nassif, A. Molina‐Leyva, Ł. Matusiak, A. V. Marzano, B. M. McGrath, A. I. Liakou, B. Kirby, L. Kemény, E. Just, D. Ioannidis, J. R. Ingram, R. E. Hunger, B. Horváth, P. Guillem, Ø. Grimstad, E. J. Giamarellos‐Bourboulis, M. Dolenc‐Voljč, V. Del Marmol, Z. Bukvić Mokos, V. Bettoli, F. Benhadou, F. G. Bechara, C. C. Zouboulis   +36 more
wiley   +1 more source

Clinical Warburg Effect in a primary cutaneous lymphoma. [PDF]

Clin Hematol Int
Martins F, Fontinha G, Magalhães J, Cardoso JC, Calvão J.   +4 more
europepmc   +1 more source

Real-life Use of Bexarotene for T-cell Cutaneous Lymphoma Management: Efficacy and Tolerance with Low Doses. [PDF]

Acta Derm Venereol, 2022
Rouanet J, Joulie I, Lambert C, D'Incan M.   +3 more
europepmc   +1 more source

Primary cutaneous acral CD8‐positive lymphoproliferative disorder of the auricles: An unusual long‐term course

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Anna Sophia Flechtenmacher, Cyrill Géraud, Jan Peter Nicolay   +2 more
wiley   +1 more source

Immune‐related adverse events with mogamulizumab in cutaneous T‐cell lymphoma: A multicentre study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In a nationwide multicentre study of 403 patients with cutaneous T‐cell lymphoma treated with mogamulizumab, non‐MAR immune‐related adverse events were reported in 8.4% of patients across responding centres. These events were diverse, sometimes severe or persistent, and could occur late during mogamulizumab treatment.
David Neubauer, Pascale Palassin, Caroline Ram‐Wolff, Adèle De Masson, Jeremie Delaleu, Diane Kottler, Florent Amatore, Henri Adamski, Claudia Bejar, Raphaël Janela‐Lapert, Emmanuella Guenova, Pauline Bernard, Coralie Lheure, Laurent Machet, Laura Troin, Gaëlle Quereux, Anne Pham‐Ledard, Sarah Faiz, Florent Grange, Yannick Le Corre, Arjen Nikkels, Stéphane Barete, Lorena Manea, Emmanuelle Amazan, Alexandre Tj Maria, Lionel Moulis, Olivier Dereure, Quentin Samaran, For the Groupe Français d'Étude des Lymphomes Cutanés (GFELC)   +28 more
wiley   +1 more source

Association of Secondary Primary Malignancies in Cutaneous Lymphoma: A Narrative Review. [PDF]

Diagnostics (Basel)
Hung YH, Hsiao PF.
europepmc   +1 more source

Cutaneous Lymphoma

Dermatologic Clinics, 2015
openaire   +2 more sources

Targeted therapies in pemphigus vulgaris: Emerging horizons beyond rituximab

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Rituximab‐refractory pemphigus vulgaris is driven by B‐cell repopulation, plasma‐cell persistence, IgG4 autoantibodies and anti‐drug antibodies. This review evaluates five emerging targeted classes acting at successive steps of disease: next‐generation anti‐CD20 antibodies, DSG3‐CAAR T cells, BTK inhibitors, BAFF/APRIL inhibitors and FcRn antagonists ...
Rhea Ahuja, Dedee Murrell
wiley   +1 more source